Controlled type II diabetes mellitus has no major influence on platelet micro-RNA expression. Results from

Christian Stratz1, Thomas Nührenberg, Bernd L Fiebich

  • 1Christian Stratz, Universitäts-Herzzentrum Freiburg - Bad Krozingen, Abteilung für Kardiologie und Angiologie II, Südring 15, D-79189 Bad Krozingen, Germany, Tel.: +49 7633 4020, Fax: +49 761 4022489,

Thrombosis and Haemostasis
|December 20, 2013
PubMed

Insights

Diabetes mellitus does not significantly alter platelet microRNA (miRNA) profiles, contrary to plasma changes. Minor differences in platelet miRNA related to mRNA processing were observed in diabetic patients.

Area of Science:

  • Cardiovascular Biology
  • Molecular Biology
  • Endocrinology

Background:

  • Diabetes mellitus is a major risk factor for cardiovascular disease.
  • Platelets contain microRNAs (miRNAs) involved in inflammation and atherogenesis.
  • Plasma miRNA profiles differ in diabetes, but platelet miRNA profiles remain uncharacterized.

Purpose of the Study:

  • To investigate platelet miRNA profiles in patients with diabetes mellitus.
  • To determine if diabetes mellitus, independent of coronary artery disease (CAD), affects platelet miRNA expression.

Main Methods:

  • Platelet miRNA profiling was performed using LNA micro-array technology on stable diabetic and non-diabetic patients.
  • Statistical analyses, including univariate tests and multivariable signature development with resampling, were used.
  • miRNA expression was compared between groups, with and without CAD.

Main Results:

  • Platelet miRNA profiles were largely similar between diabetic and non-diabetic individuals.
  • Three specific miRNAs (miR-377-5p, miR-628-3p, miR-3137) showed minor differences linked to mRNA processing.
  • No major differences in platelet miRNA profiles explained observed plasma miRNA alterations in diabetes.

Conclusions:

  • Diabetes mellitus does not cause substantial changes in platelet miRNA profiles.
  • Observed differences in plasma miRNAs in diabetes are not attributable to altered platelet miRNA expression.
  • Further research is needed to understand the role of platelet miRNAs in diabetic cardiovascular complications.

Related Concept Videos

Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
75
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
17
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K